Hooshmand Sheshbaradaran
Operationeel Directeur bij BETTERLIFE PHARMA INC.
Vermogen: 103 971 $ op 30-04-2024
Actieve functies van Hooshmand Sheshbaradaran
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BETTERLIFE PHARMA INC. | Operationeel Directeur | - | - |
Niiki Pharma, Inc.
Niiki Pharma, Inc. Pharmaceuticals: OtherHealth Technology Niiki Pharma, Inc. manufactures chemicals and botanical products. It specializes in cancer treatments directed at novel cellular targets and related companion diagnostics. The company was founded by Hooshmand Sheshbaradaran, Ardakana Ali and Jay Z. Zhang in 2007 and is headquartered in Hoboken, NJ. | President | - | - |
Oprichter | - | - | |
Algemeen Directeur | 01-01-2007 | - | |
Bold Therapeutics, Inc.
Bold Therapeutics, Inc. BiotechnologyHealth Technology Bold Therapeutics, Inc. is a Canadian clinical-stage biopharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company is based in Vancouver, Canada. The company's focus is on developing Bold-100, a drug that has the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies. Edward Russell McAllister has been the CEO of the company since 2018. | Directeur/Bestuurslid | 01-01-2019 | - |
Loopbaan van Hooshmand Sheshbaradaran
Eerdere bekende functies van Hooshmand Sheshbaradaran
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Intezyne Technologies, Inc.
Intezyne Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Intezyne Technologies, Inc. develops therapeutic and diagnostic technologies. The firm is a clinical stage biotechnology company. The company was founded by Habib Skaff and Kevin N. Sill in 2004 and is headquartered in Tampa, FL. | Directeur/Bestuurslid | 19-06-2013 | 02-01-2019 |
Corporate Officer/Principal | 19-06-2013 | - | |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Corporate Officer/Principal | - | - |
PFIZER, INC. | Verkoop & Marketing | - | - |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Verkoop & Marketing | - | - |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - | - |
Zeneus Pharma Ltd.
Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Corporate Officer/Principal | - | - |
Opleiding van Hooshmand Sheshbaradaran
Karolinska Institutet | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Verenigd Koninkrijk | 3 |
Canada | 3 |
Operationeel
Corporate Officer/Principal | 4 |
Sales & Marketing | 2 |
Director/Board Member | 2 |
Sectoraal
Health Technology | 8 |
Distribution Services | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
PFIZER, INC. | Health Technology |
BETTERLIFE PHARMA INC. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Zeneus Pharma Ltd.
Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Distribution Services |
Niiki Pharma, Inc.
Niiki Pharma, Inc. Pharmaceuticals: OtherHealth Technology Niiki Pharma, Inc. manufactures chemicals and botanical products. It specializes in cancer treatments directed at novel cellular targets and related companion diagnostics. The company was founded by Hooshmand Sheshbaradaran, Ardakana Ali and Jay Z. Zhang in 2007 and is headquartered in Hoboken, NJ. | Health Technology |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Intezyne Technologies, Inc.
Intezyne Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Intezyne Technologies, Inc. develops therapeutic and diagnostic technologies. The firm is a clinical stage biotechnology company. The company was founded by Habib Skaff and Kevin N. Sill in 2004 and is headquartered in Tampa, FL. | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Bold Therapeutics, Inc.
Bold Therapeutics, Inc. BiotechnologyHealth Technology Bold Therapeutics, Inc. is a Canadian clinical-stage biopharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company is based in Vancouver, Canada. The company's focus is on developing Bold-100, a drug that has the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies. Edward Russell McAllister has been the CEO of the company since 2018. | Health Technology |